Contact
searchSearch
HMP Global

First Report Managed Care

News

News
Osimertinib Demonstrates a Manageable Safety Profile Among Patients With NSCLC After Definitive CRT
07/13/2026
Rebecca Amrick
In the phase 3 LAURA clinical trial, osimertinib demonstrated a tolerable safety profile when used to treat patients with non–small cell lung cancer (NSCLC) after definitive chemoradiotherapy (CRT).
In the phase 3 LAURA clinical trial, osimertinib demonstrated a tolerable safety profile when used to treat patients with non–small cell lung cancer (NSCLC) after definitive chemoradiotherapy (CRT).
In the phase 3 LAURA clinical...
07/13/2026
First Report Managed Care
News
Longer Hemodialysis Treatment Time Linked to Improved Survival in US Cohort
07/10/2026
Grace Taylor, MS, MA
A large US study found that extending in-center hemodialysis treatment time to approximately 4 hours was associated with lower mortality, fewer hospitalizations, and shorter hospital stays, highlighting a potentially modifiable factor in...
A large US study found that extending in-center hemodialysis treatment time to approximately 4 hours was associated with lower mortality, fewer hospitalizations, and shorter hospital stays, highlighting a potentially modifiable factor in...
A large US study found that...
07/10/2026
First Report Managed Care
Behind the Bill
CMS Proposes Broad Changes to Medicare Home Health Payment and Oversight
07/10/2026
Hannah Musick
The Centers for Medicare & Medicaid Services’ (CMS) proposed 2027 Home Health Prospective Payment System rule goes beyond a routine payment update, introducing changes to reimbursement, quality reporting, provider oversight, and program...
The Centers for Medicare & Medicaid Services’ (CMS) proposed 2027 Home Health Prospective Payment System rule goes beyond a routine payment update, introducing changes to reimbursement, quality reporting, provider oversight, and program...
The Centers for Medicare &...
07/10/2026
First Report Managed Care
News
TKI Discontinuation Supports Long-Term Treatment-Free Remission in Chronic-Phase CML
07/08/2026
Grace Taylor, MS, MA
A meta-analysis of 16 studies found that approximately half of patients with chronic-phase chronic myeloid leukemia (CML) remained in treatment-free remission for up to 36 months after discontinuing tyrosine kinase inhibitor (TKI) therapy,...
A meta-analysis of 16 studies found that approximately half of patients with chronic-phase chronic myeloid leukemia (CML) remained in treatment-free remission for up to 36 months after discontinuing tyrosine kinase inhibitor (TKI) therapy,...
A meta-analysis of 16 studies...
07/08/2026
First Report Managed Care
News
Tirzepatide Demonstrates Improved Clinical Benefit and Lower Costs than Semaglutide in Adults With Obesity
07/08/2026
Rebecca Amrick
A simulation model demonstrated that tirzepatide had better clinical outcomes and less medical costs than semaglutide for patients with obesity or overweight, supporting prior research that highlighted tirzepatide as a viable treatment...
A simulation model demonstrated that tirzepatide had better clinical outcomes and less medical costs than semaglutide for patients with obesity or overweight, supporting prior research that highlighted tirzepatide as a viable treatment...
A simulation model demonstrated...
07/08/2026
First Report Managed Care
News
Electronic Interventions Could Reduce Reliance on Benzodiazepines
07/06/2026
Rebecca Amrick
Electronic interventions could allow patients taking benzodiazepines to actively manage their prescriptions and reduce drug reliance, which would improve self-management of care without excessive cost burdens.
Electronic interventions could allow patients taking benzodiazepines to actively manage their prescriptions and reduce drug reliance, which would improve self-management of care without excessive cost burdens.
Electronic interventions could...
07/06/2026
First Report Managed Care
News
Real-World Study Supports Omalizumab for Food Allergy Management
07/02/2026
Hannah Musick
Real-world data suggest that omalizumab enabled most patients with food allergy to successfully tolerate oral food challenges and introduce previously allergenic foods into their diets, with generally manageable allergic reactions during...
Real-world data suggest that omalizumab enabled most patients with food allergy to successfully tolerate oral food challenges and introduce previously allergenic foods into their diets, with generally manageable allergic reactions during...
Real-world data suggest that...
07/02/2026
First Report Managed Care
Behind the Bill
House Advances Bipartisan Legislation to Ease Quality Reporting Burden for Medicare ACOs
07/02/2026
Grace Taylor, MS, MA
The US House of Representatives (House) unanimously approved H.R. 5347, bipartisan legislation that would provide greater flexibility for Medicare Accountable Care Organizations (ACOs) transitioning to digital quality reporting.
The US House of Representatives (House) unanimously approved H.R. 5347, bipartisan legislation that would provide greater flexibility for Medicare Accountable Care Organizations (ACOs) transitioning to digital quality reporting.
The US House of Representatives...
07/02/2026
First Report Managed Care
Behind the Bill
Medicare Cost Cap Act Would Establish Out-of-Pocket Maximum in Traditional Medicare
06/26/2026
Grace Taylor, MS, MA
The Medicare Cost Cap Act would establish the first annual out-of-pocket spending limit in traditional Medicare, a change that could reshape beneficiary affordability and the competitive landscape across Medicare coverage options.
The Medicare Cost Cap Act would establish the first annual out-of-pocket spending limit in traditional Medicare, a change that could reshape beneficiary affordability and the competitive landscape across Medicare coverage options.
The Medicare Cost Cap Act would...
06/26/2026
First Report Managed Care
News
Omalizumab Associated With Reduced HCRU and Disease-Related Costs for Food Allergies and Asthma
06/25/2026
Rebecca Amrick
Omalizumab shows promise in reducing health care resource utilization (HCRU) and associated care costs for patients with comorbid food allergies and asthma, according to a study published in the Journal of Allergy and Clinical Immunology:...
Omalizumab shows promise in reducing health care resource utilization (HCRU) and associated care costs for patients with comorbid food allergies and asthma, according to a study published in the Journal of Allergy and Clinical Immunology:...
Omalizumab shows promise in...
06/25/2026
First Report Managed Care

KOL Insights

J Collins
Commentary
Time is Therapy: What Managed Care Can Learn from Individuals Navigating Infusion Access
07/14/2026
A patient panel at the 2026 National Infusion Center Association (NICA) Annual Conference underscored how delays driven by prior authorization, benefit design, and administrative barriers can profoundly affect the lives of individuals with...
A patient panel at the 2026 National Infusion Center Association (NICA) Annual Conference underscored how delays driven by prior authorization, benefit design, and administrative barriers can profoundly affect the lives of individuals with...
A patient panel at the 2026...
07/14/2026
First Report Managed Care
MANAGED CARE Q&A
From Innovation to Access: Overcoming Reimbursement Challenges for Cell and Gene Therapies
06/25/2026
Joe DePinto
This interview explores the structural, operational, and reimbursement challenges limiting access to cell and gene therapies, highlighting the importance of stakeholder collaboration, innovative payment models, real-world evidence, and...
This interview explores the structural, operational, and reimbursement challenges limiting access to cell and gene therapies, highlighting the importance of stakeholder collaboration, innovative payment models, real-world evidence, and...
This interview explores the...
06/25/2026
First Report Managed Care
Commentary
Through the Payer Lens: Real‑World Evidence That Changes Access
06/25/2026
Chris Terrone; Cynthia Miller; Mitch DeKoven
As regulators and payers place growing emphasis on real-world evidence, new survey findings reveal what managed care decision-makers value most—and how manufacturers can generate and communicate evidence that meaningfully influences coverage...
As regulators and payers place growing emphasis on real-world evidence, new survey findings reveal what managed care decision-makers value most—and how manufacturers can generate and communicate evidence that meaningfully influences coverage...
As regulators and payers place...
06/25/2026
First Report Managed Care
Commentary
Twenty Years of Value-Based Care: Industry Leaders on What's Next
06/25/2026
Patty Hayward; David Lareau; Jeanne Cohen; Alexandria Foley, MSN, RN; Kevin Ritter; Payam Zamani, MD; Eugene Gonsiorek; Mike Camacho; Joseph Kleiman; Bill Kerr, MD
To mark the 20th anniversary of value-based care, health care innovation and value-based care leaders reflect on how the industry has evolved—and why success over the next 20 years will depend on moving from payment reform to the...
To mark the 20th anniversary of value-based care, health care innovation and value-based care leaders reflect on how the industry has evolved—and why success over the next 20 years will depend on moving from payment reform to the...
To mark the 20th anniversary of...
06/25/2026
First Report Managed Care
Commentary
From Risk Scores to Real Outcomes: Why Having More Data Isn’t Solving the Medication Adherence Problem
06/25/2026
Chandra Y. Osborn, PhD, MPH
As managed care shifts toward outcomes-based performance, health plans are discovering that identifying at-risk members is no longer enough—the real competitive advantage lies in driving sustained behavior change to improve medication...
As managed care shifts toward outcomes-based performance, health plans are discovering that identifying at-risk members is no longer enough—the real competitive advantage lies in driving sustained behavior change to improve medication...
As managed care shifts toward...
06/25/2026
First Report Managed Care
Regulatory Insights
Congress Shifts Focus as Health Policy Scrutiny Continues
06/25/2026
Adam Colborn, JD
Although major legislative activity has slowed following pharmacy benefit manager (PBM) reform, ongoing congressional scrutiny of drug patents, price transparency, broker compensation, and the future of Medicare Star Ratings signals that...
Although major legislative activity has slowed following pharmacy benefit manager (PBM) reform, ongoing congressional scrutiny of drug patents, price transparency, broker compensation, and the future of Medicare Star Ratings signals that...
Although major legislative...
06/25/2026
First Report Managed Care
Debra Patt
Interview
How Electronic Patient-Reported Outcomes Are Transforming Symptom Management and Value-Based Cancer Care
06/19/2026
Debra A. Patt, MD, PhD, MBA
In this interview, Deborah Patt, MD, PhD, MBA, discusses data presented at the 2026 American Society of Clinical Oncology Annual Meeting showing how electronic patient-reported outcomes and remote therapeutic monitoring can improve symptom...
In this interview, Deborah Patt, MD, PhD, MBA, discusses data presented at the 2026 American Society of Clinical Oncology Annual Meeting showing how electronic patient-reported outcomes and remote therapeutic monitoring can improve symptom...
In this interview, Deborah Patt,...
06/19/2026
First Report Managed Care
Jill Hellmann
Interview
Rethinking Cancer Attribution in Value-Based Oncology Care
06/03/2026
Jill Hellmann, MSN, RN
In this interview, a guest expert discusses research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on how the growing use of oral oncolytics and the increasing prevalence of concurrent cancers may expose...
In this interview, a guest expert discusses research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on how the growing use of oral oncolytics and the increasing prevalence of concurrent cancers may expose...
In this interview, a guest...
06/03/2026
First Report Managed Care
Nephrology, kidney disease
Managed Care Insights
The Evolving Nephrology Landscape: Treatment, Innovation, and Policy: Part 3
05/29/2026
Suzanne Watnick, MD
Suzanne Watnick, MD, explains why earlier chronic kidney disease detection, broader access to proven therapies, and reimbursement policies that support innovation are critical to improving kidney care outcomes and reducing progression to...
Suzanne Watnick, MD, explains why earlier chronic kidney disease detection, broader access to proven therapies, and reimbursement policies that support innovation are critical to improving kidney care outcomes and reducing progression to...
Suzanne Watnick, MD, explains...
05/29/2026
First Report Managed Care
Nephrology, kidney disease
Managed Care Insights
The Evolving Nephrology Landscape: Treatment, Innovation, and Policy: Part 2
05/29/2026
Suzanne Watnick, MD
Dr Suzanne Watnick examines how greater investment, equitable policies, and stakeholder collaboration will be essential to ensuring that emerging kidney therapies improve outcomes without widening existing disparities in care.
Dr Suzanne Watnick examines how greater investment, equitable policies, and stakeholder collaboration will be essential to ensuring that emerging kidney therapies improve outcomes without widening existing disparities in care.
Dr Suzanne Watnick examines how...
05/29/2026
First Report Managed Care

Issue Features

Infographic
Extended Findings With Nerandomilast in Idiopathic Pulmonary Fibrosis (IPF)
05/21/2026
The infographic summarizes 76-week study data from the phase 3 FIBRONEER-IPF trial to provide additional insights on lung function trends, disease progression, mortality risk, and safety outcomes over time with nerandomilast.
The infographic summarizes 76-week study data from the phase 3 FIBRONEER-IPF trial to provide additional insights on lung function trends, disease progression, mortality risk, and safety outcomes over time with nerandomilast.
The infographic summarizes...
05/21/2026
First Report Managed Care
Sponsored
Explore the Clinical Data for JOURNAVX® (suzetrigine)
10/16/2025
JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain in adults—the first and only oral pain signal inhibitor highly selective for NaV1.81
JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain in adults—the first and only oral pain signal inhibitor highly selective for NaV1.81
JOURNAVX is an oral nonopioid...
10/16/2025
First Report Managed Care
Infographic
Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis
08/06/2025
The infographic summarizes the FIBRONEER-IPF Phase 3 trial results, demonstrating nerandomilast significantly reduced the decline in forced vital capacity (FVC) over 52 weeks compared to placebo. Nerandomilast exhibited a favorable safety...
The infographic summarizes the FIBRONEER-IPF Phase 3 trial results, demonstrating nerandomilast significantly reduced the decline in forced vital capacity (FVC) over 52 weeks compared to placebo. Nerandomilast exhibited a favorable safety...
The infographic summarizes the...
08/06/2025
First Report Managed Care
Feature Story
More Specialists Should Gravitate Toward Episode-Based Care Models
05/12/2025
Lynn Carroll; Rahul Sharma
Health care organizations will be under increasing financial pressure in 2025 and beyond as they struggle to reduce costs while improving care quality—particularly as actions at the federal level threaten to severely disrupt the industry. Not...
Health care organizations will be under increasing financial pressure in 2025 and beyond as they struggle to reduce costs while improving care quality—particularly as actions at the federal level threaten to severely disrupt the industry. Not...
Health care organizations will...
05/12/2025
First Report Managed Care
Feature Story
Winning With Value-Based Care: Balancing Risk, Analytics, and Digital Innovation
05/12/2025
David J. Sand, MD, MBA; Lynn Carroll
Value-based care (VBC) is the future of health care. It is the best approach to improving patient outcomes, reducing costs and addressing overall population health through a focus on prevention, care coordination and overall wellness.
Value-based care (VBC) is the future of health care. It is the best approach to improving patient outcomes, reducing costs and addressing overall population health through a focus on prevention, care coordination and overall wellness.
Value-based care (VBC) is the...
05/12/2025
First Report Managed Care

Interactive Features

Poll
Evaluating Treatment Options for Advanced Squamous Cell Carcinoma of the Anal Canal
06/18/2026
Do you think retifanlimab plus carboplatin/paclitaxel should be adopted as the new frontline standard of care for patients with advanced squamous cell carcinoma of the anal canal?
Do you think retifanlimab plus carboplatin/paclitaxel should be adopted as the new frontline standard of care for patients with advanced squamous cell carcinoma of the anal canal?
Do you think retifanlimab plus...
06/18/2026
First Report Managed Care
Quiz
First-Line Immunotherapy in Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC): Pre-Test
03/31/2026
03/31/2026
First Report Managed Care
PIPELINE PROJECTIONS
Emerging Therapies Reshaping Atopic Dermatitis Care
03/26/2026
Roy Moore
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly...
03/26/2026
First Report Managed Care
Quiz
Monitoring AI Automation
11/25/2025
True or False: The transformation of traditional health care call centers into “smart access hubs” relies entirely on artificial intelligence (AI) to manage all patient interactions and scheduling.
True or False: The transformation of traditional health care call centers into “smart access hubs” relies entirely on artificial intelligence (AI) to manage all patient interactions and scheduling.
True or False: The...
11/25/2025
First Report Managed Care
Quiz
Mobile Health’s Expanding Role in Bridging Care Gaps Across the US
11/11/2025
11/11/2025
First Report Managed Care

Pipeline Projections

PIPELINE PROJECTIONS
Emerging Therapies Reshaping Atopic Dermatitis Care
03/26/2026
Roy Moore
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly...
03/26/2026
First Report Managed Care
Pipe
Pipeline Projections
Emerging Migraine Treatments Challenge a Mature Market
11/20/2025
Roy Moore
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market...
11/20/2025
First Report Managed Care
Pipeline Projections
Pipeline Projections
Redefining Asthma Management With Emerging Anti-Inflammatories
10/01/2025
Roy Moore
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access...
10/01/2025
First Report Managed Care
Pipeline Projections
The Shift in MS Care as Biologics and BTK Inhibitors Advance
07/25/2025
Roy Moore
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline...
07/25/2025
First Report Managed Care
Pipeline Projections
How Biosimilars Are Shaping RA Treatment and Reimbursement Strategies
04/29/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline...
04/29/2025
First Report Managed Care

Subscribe to receive the latest updates in managed care!

First Report Managed Care Newsletter

Behind the Bill

Behind the Bill
HHS Hits Reset on 340B Rebate Model After Court Setbacks
02/11/2026
Juliet Gallagher
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and...
02/11/2026
First Report Managed Care
Behind the Bill
Funding Package Extends Medicare Telehealth, Enacts PBM Reforms, and Updates Hospital Oversight
02/05/2026
Juliet Gallagher
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President...
02/05/2026
First Report Managed Care
Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use